Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India
A retrospective medical chart review from India evaluating outcomes of chronic lymphocytic leukemia and mantle cell lymphoma patients treate…
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]
A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.
-
FDA approval · 2025-01-31FDA Approved: LENALIDOMIDE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved Amneal Pharmaceuticals NY LLC's generic lenalidomide (LENALIDOMIDE) under an Original Application (ANDA 216213).
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) [Phase 2]
Phase 2 trial evaluating acalabrutinib in patients with chronic lymphocytic leukemia and mantle cell lymphoma after allogeneic stem cell tra…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating venetoclax in combination with ibrutinib in adult Japanese participants with relapsed/refractory mantle cell lymp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
This Phase 2 trial evaluates ibrutinib in combination with rituximab for relapsed or refractory mantle cell lymphoma. The study has complete…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS research · 2025-01-10Clinical Trial Update: Real-world Study of Acalabrutinib
A real-world study of acalabrutinib sponsored by Ruijin Hospital is enrolling by invitation, investigating its use in mantle cell lymphoma a…
-
CLINICAL_TRIALS other · 2024-12-27Clinical Trial Update: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL [Phase 3]
This ClinicalTrials.gov listing describes a global Phase 3 study evaluating orelabrutinib plus bendamustine-rituximab (BR) versus BR alone i…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors [Phase 1, Phase 2]
An update on the Phase 1/2 study of CYT-0851 in B-cell malignancies and advanced solid tumors, noting completion of Phase 1/2 cohorts.
-
CLINICAL_TRIALS approval · 2024-12-18Clinical Trial Update: Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
The document notes that pirtobrutinib is approved for marketing in relation to an expanded access program for multiple B-cell cancers, cover…
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
A Phase 2 study evaluating ixazomib in combination with rituximab for relapsed or refractory mantle cell lymphoma was terminated, with resul…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 trial evaluating SD-101 (TLR9 agonist) and BMS-986178 (anti-OX40 antibody) with radiation therapy for low-grade B-cell non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma [Phase 4]
Phase 4 clinical trial update: acalabrutinib in Indian patients with chronic lymphocytic leukemia and relapsed/refractory mantle cell lympho…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma [Phase 2]
A prospective, single-center Phase 2 study assessing the efficacy and safety of combining Glofitamab with Orelabrutinib and Bortezomib in hi…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
Early-phase study evaluating the safety and preliminary efficacy of combining ibrutinib with pembrolizumab in chronic lymphocytic leukemia o…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a combination of tafasitamab, lenalidomide and venetoclax for relapsed or refractory mantle cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]
A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been term…
-
CLINICAL_TRIALS research · 2024-11-07Clinical Trial Update: Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma [Phase 2]
A Phase 2 clinical trial update describing the investigation of combining tisagenlecleucel with ibrutinib for mantle cell lymphoma, currentl…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of bendamustine plus obinutuzumab induction with obinutuzumab maintenance in untreated mantle cell lymphoma; the study is term…
-
CLINICAL_TRIALS research · 2024-10-18Clinical Trial Update: Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL [Phase 2]
Phase 2 trial investigating zanubrutinib and rituximab followed by R-DHAOx and zanubrutinib maintenance for newly diagnosed mantle cell lymp…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating SD-101 (TLR9 agonist) combined with Ibrutinib and radiation therapy in relapsed or refractory follicular lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
Pfizer-sponsored STAR-TOR registry study update reports completion and posted results for a three-drug regimen of temsirolimus, sunitinib, a…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 study of a four-drug regimen (polatuzumab vedotin, venetoclax, rituximab, and hyaluronidase) in relapsed or refractory mantle cell l…
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms [Phase 1]
Phase 1 trial of CD19-targeted CAR T cells for refractory/relapsed CD19-positive B-cell neoplasms (ALL, mantle cell lymphoma, diffuse large …